Sangamo Therapeutics (SGMO)
NASDAQ:SGMO
Want to see SGMO full AI Analyst Report?
SGMO Stock Chart & Stats
$0.26
-$0.13(-9.49%)
At close: 4:00 PM EST
$0.26
-$0.13(-9.49%)
Day’s Range― - ―
52-Week Range$0.12 - $0.78
Previous CloseN/A
Volume2.84M
Average Volume (3M)7.65M
Market Cap
$55.93M
Enterprise Value$60.86M
Total Cash (Recent Filing)$20.95M
Total Debt (Recent Filing)$26.80M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding414,274,020
10 Day Avg. Volume4,237,466
30 Day Avg. Volume7,646,780
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-8.25
Price to Sales (P/S)2.98
P/FCF Ratio-1.21
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue1.54
Enterprise Value/Gross Profit1.90
Enterprise Value/Ebitda-0.60
Forecast
1Y Price Target
$6.00Price Target Upside2207.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.17
Revenue Forecast (FY)$80.33M
Bulls Say, Bears Say
Bulls Say
Durability And Safety ProfileDurable supraphysiologic alpha-Gal A expression with sustained substrate control after a single infusion, combined with long-term follow-up showing no late-emerging safety signals, de-risks the therapy's long-term benefit and supports physician adoption.
Regulatory Approval PathwayCompletion and acceptance of the biologics license application for the Fabry gene therapy would be a major value catalyst by enabling potential commercial authorization.
Renal Efficacy And Regulatory EndpointSustained improvement in kidney function and renal analyses validating estimated glomerular filtration rate slope as a durable clinical endpoint strengthen the approval case and commercial differentiation.
Bears Say
CMC And Regulatory ReadinessIncomplete chemistry, manufacturing and controls documentation and outstanding stability data represent a final gating factor for the biologics license application and could delay regulatory readiness.
Funding And Partnership RiskA limited cash runway makes the outcome of partnering discussions the primary value driver, introducing funding risk that could impede completion of regulatory and commercialization activities.
Manufacturing Scale-up DependencyFinishing commercial and validated process lots depends on securing additional funding from a potential commercialization partner, creating execution risk for manufacturing scale-up.
Sangamo Therapeutics News
SGMO FAQ
What was Sangamo Therapeutics’s price range in the past 12 months?
Sangamo Therapeutics lowest stock price was $0.12 and its highest was $0.78 in the past 12 months.
What is Sangamo Therapeutics’s market cap?
Sangamo Therapeutics’s market cap is $55.93M.
When is Sangamo Therapeutics’s upcoming earnings report date?
Sangamo Therapeutics’s upcoming earnings report date is May 18, 2026 which is in 15 days.
How were Sangamo Therapeutics’s earnings last quarter?
Sangamo Therapeutics released its earnings results on Mar 30, 2026. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of $0.009 by -$0.119.
Is Sangamo Therapeutics overvalued?
According to Wall Street analysts Sangamo Therapeutics’s price is currently Undervalued.
Does Sangamo Therapeutics pay dividends?
Sangamo Therapeutics does not currently pay dividends.
What is Sangamo Therapeutics’s EPS estimate?
Sangamo Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sangamo Therapeutics have?
Sangamo Therapeutics has 414,274,020 shares outstanding.
What happened to Sangamo Therapeutics’s price movement after its last earnings report?
Sangamo Therapeutics reported an EPS of -$0.11 in its last earnings report, missing expectations of $0.009. Following the earnings report the stock price went down -19.87%.
Which hedge fund is a major shareholder of Sangamo Therapeutics?
Currently, no hedge funds are holding shares in SGMO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sangamo Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (2207.69% Upside)
$6.00 (2207.69% Upside)
Hedge Fund Trend
Increased
By 58.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $103.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-81.70%
12-Months-Change
Fundamentals
Return on Equity
-2983.24%
Trailing 12-Months
Asset Growth
-42.54%
Trailing 12-Months
Company Description
Sangamo Therapeutics
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
SGMO Company Deck
SGMO Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced substantial clinical and regulatory progress — including positive pivotal Fabry data, a rolling BLA submission with clinical and nonclinical modules filed, manufacturing milestones, >$130M raised, Fast Track designation, and a strategic capsid license with a major partner — against material financial and timing risks. The company made important scientific and regulatory advances but continues to face unresolved long-term cash runway concerns, partnership delays, and CMC-driven timeline extensions that are critical to achieving approval and commercialization.View all SGMO earnings summariesSGMO Stock 12 Month Forecast
Average Price Target
$6.00
▲(2207.69% Upside)
Technical Analysis
―
Cabaletta Bio
―
Black Diamond Therapeutics
―
Elicio Therapeutics
―
Caribou Biosciences
―
Ownership Overview
1.13% Insiders
4.84% Mutual Funds
0.27% Other Institutional Investors
89.84% Public Companies and
Individual Investors